We are live on ! Find out more
SCA

Spearhead Capital Advisors Portfolio holdings

AUM $92.3M
1-Year Est. Return 18.16%
This Fund
S&P 500
This Quarter Est. Return
+7.56%
1 Year Est. Return
-18.16%
3 Year Est. Return
+25.24%
5 Year Est. Return
+54.04%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$57.8M
Cap. Flow
+$11.1M
Cap. Flow %
1.5%
Top 10 Hldgs %
31.1%
Holding
195
New
10
Increased
148
Reduced
29
Closed
4

Top Buys

Rank Stock Value
1
GBDC icon
Golub Capital BDC
GBDC
+$2.33M
2
AAPL icon
Apple
AAPL
+$1.25M
3
BE icon
Bloom Energy
BE
+$903K
4
MLPB icon
ETRACS Alerian MLP Infrastructure Index ETN Series B due Apr 2 2040
MLPB
+$552K
5
CRM icon
Salesforce
CRM
+$365K

Top Sells

Rank Stock Value
1
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$2.15M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$601K
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$576K
4
GLUU
Glu Mobile Inc.
GLUU
+$503K
5
MRNA icon
Moderna
MRNA
+$495K

Sector Composition

Rank Sector Weight
1 Miscellaneous 23.9%
2 Technology 15.29%
3 Healthcare 12.07%
4 Consumer Staples 10.97%
5 Financials 10.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
Z icon
151
Zillow
Z
$7.18B
$384K 0.05%
3,139
+410
+15% +$49.9K
EHTH icon
152
eHealth
EHTH
$28.4M
$383K 0.05%
6,555
+632
+11% +$41.6K
FSLY icon
153
Fastly Inc
FSLY
$3.9B
$380K 0.05%
+6,377
New +$362K
QTRX icon
154
Quanterix
QTRX
$137M
$379K 0.05%
6,464
+1,029
+19% +$59.7K
CRSP icon
155
CRISPR Therapeutics
CRSP
$5.11B
$374K 0.05%
2,310
-1,396
-38% -$170K
MRNA icon
156
Moderna
MRNA
$58.5B
$372K 0.05%
1,583
-2,771
-64% -$495K
CORT icon
157
Corcept Therapeutics
CORT
$12.1B
$367K 0.05%
16,692
+2,487
+18% +$55.3K
PLAN
158
DELISTED
Anaplan, Inc.
PLAN
$364K 0.05%
6,835
+926
+16% +$51.5K
GH icon
159
Guardant Health
GH
$23.6B
$363K 0.05%
2,925
+322
+12% +$43.3K
EVER icon
160
EverQuote
EVER
$851M
$362K 0.05%
11,068
+1,641
+17% +$54.7K
VCLT icon
161
Vanguard Long-Term Corporate Bond ETF
VCLT
$8.86B
$355K 0.05%
3,316
+377
+13% +$39K
CHRS icon
162
Coherus Oncology
CHRS
$199M
$354K 0.05%
25,608
+4,179
+20% +$59.2K
OTRK
163
DELISTED
Ontrak
OTRK
$354K 0.05%
121
+33
+38% +$95.3K
VGLT icon
164
Vanguard Long-Term Treasury ETF
VGLT
$10.4B
$352K 0.05%
4,010
+383
+11% +$32.5K
KPTI icon
165
Karyopharm Therapeutics
KPTI
$38.1M
$351K 0.05%
2,269
+467
+26% +$67.8K
OCUL icon
166
Ocular Therapeutix
OCUL
$2.22B
$342K 0.05%
24,134
+3,853
+19% +$58.6K
NVTA
167
DELISTED
Invitae Corporation
NVTA
$341K 0.05%
10,108
+1,703
+20% +$55.4K
PTCT icon
168
PTC Therapeutics
PTCT
$5.59B
$337K 0.05%
7,962
+1,463
+23% +$62.7K
ESGE icon
169
iShares ESG Aware MSCI EM ETF
ESGE
$6.88B
$327K 0.04%
7,249
+36
+0.5% +$1.59K
NVDA icon
170
NVIDIA
NVDA
$5.21T
$327K 0.04%
16,360
-9,160
-36% -$147K
ILMN icon
171
Illumina
ILMN
$34.5B
$326K 0.04%
708
-44
-6% -$17.7K
VAW icon
172
Vanguard Materials ETF
VAW
$2.94B
$317K 0.04%
1,753
-130
-7% -$24K
IRTC icon
173
iRhythm Holdings
IRTC
$3.73B
$316K 0.04%
4,768
+2,789
+141% +$221K
RARE icon
174
Ultragenyx Pharmaceutical
RARE
$1.27B
$316K 0.04%
3,318
+550
+20% +$57.3K
ACAD icon
175
Acadia Pharmaceuticals
ACAD
$4.7B
$311K 0.04%
+12,751
New +$288K
4 5 6
7
8

Similar funds

AAM
Artha Asset Management Hoboken, New Jersey $90.3M AUM 27.65% 1-Year Est. Return
AEPBI
AH Equity Partners Bio III Menlo Park, California $95M AUM 50.1% 1-Year Est. Return
MW
Milestone Wealth Buffalo, New York $89.5M AUM 17.2% 1-Year Est. Return
SC
Sarissa Consulting Santa Monica, California $96.9M AUM 29.32% 1-Year Est. Return
NIM
NuWave Investment Management Parsippany, New Jersey $87.2M AUM 38.54% 1-Year Est. Return
WIM
Wilen Investment Management Bonita Springs, Florida $98.1M AUM 2.08% 1-Year Est. Return
LAM
LFS Asset Management San Ramon, California $99.1M AUM
EFEM
Eos Focused Equity Management New York $84.5M AUM 17.48% 1-Year Est. Return

Spearhead Capital Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Spearhead Capital Advisors held 195 positions worth $735M, up 8.5% from $677M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Spearhead Capital Advisors's Q2 2021 filing shows 10 new, 148 increased, 29 reduced and 4 closed positions. Its largest new stake was Golub Capital BDC: 150,000 shares worth $2.31M. The largest sale was Kiniksa Pharmaceuticals, an estimated $2.15M.

By sector, the portfolio is most concentrated in Miscellaneous at 24% of assets, down from 24% a quarter earlier, followed by Technology and Healthcare.

  • Spearhead Capital Advisors's largest Q2 2021 buy was Golub Capital BDC: 150,000 shares worth $2.31M.
  • Spearhead Capital Advisors added most to Apple in Q2 2021, an estimated $1.25M increase.
  • Spearhead Capital Advisors's biggest Q2 2021 reduction was Kiniksa Pharmaceuticals, cutting an estimated $2.15M.
  • Spearhead Capital Advisors fully exited GenMark Diagnostics, Inc in Q2 2021, selling an estimated $576K.
  • Spearhead Capital Advisors's ten largest holdings make up 31% of its $735M portfolio in Q2 2021.
  • Spearhead Capital Advisors opened 10 new positions and closed 4 in Q2 2021.
  • Spearhead Capital Advisors's portfolio value rose 8.5% quarter-over-quarter to $735M.

Based on Spearhead Capital Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.